Eurocine Vaccines Challenges the Flu
While Australia has faced one of the harshest influenza seasons of decades[1] , Eurocine Vaccines prepares for the next phase of development, a second clinical study with its first vaccine candidate Immunose™ FLU, to fight the same.
Empowered by the two recently granted patents, in Australia and USA, and positive results from the recently conducted clinical study, Eurocine Vaccines now takes the next step towards the vision - creating the first nasal influenza vaccine approved for children under the age of two.
[1]